Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program.
Alessia PellerinoRiccardo SoffiettiFrancesco BrunoRoberta MannaErminia MuscolinoPierangela BottaRosa PalmieroRoberta RudàPublished in: Cancers (2022)
This small series shows that the combination of neratinib and capecitabine is a safe treatment in LM from heavily pretreated HER2-positive BC with clinical efficacy in some patients and is worth investigating in a larger study.
Keyphrases
- positive breast cancer
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- squamous cell carcinoma
- small cell lung cancer
- peritoneal dialysis
- clinical trial
- locally advanced
- phase ii study
- quality improvement
- radiation therapy
- metastatic breast cancer
- brain metastases
- placebo controlled